1. Home
  2. PK vs GPCR Comparison

PK vs GPCR Comparison

Compare PK & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Park Hotels & Resorts Inc.

PK

Park Hotels & Resorts Inc.

HOLD

Current Price

$14.93

Market Cap

2.8B

Sector

Real Estate

ML Signal

HOLD

Logo Structure Therapeutics Inc.

GPCR

Structure Therapeutics Inc.

HOLD

Current Price

$48.69

Market Cap

2.8B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PK
GPCR
Founded
1946
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.8B
IPO Year
2014
2023

Fundamental Metrics

Financial Performance
Metric
PK
GPCR
Price
$14.93
$48.69
Analyst Decision
Hold
Strong Buy
Analyst Count
9
12
Target Price
$11.22
$103.17
AVG Volume (30 Days)
5.2M
808.9K
Earning Date
04-30-2026
05-08-2026
Dividend Yield
8.82%
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
$2,791,000,000.00
N/A
Revenue This Year
$2.40
N/A
Revenue Next Year
$2.76
N/A
P/E Ratio
$292.70
N/A
Revenue Growth
2.35
N/A
52 Week Low
$9.84
$15.80
52 Week High
$14.95
$94.90

Technical Indicators

Market Signals
Indicator
PK
GPCR
Relative Strength Index (RSI) 66.43 50.39
Support Level $10.14 $42.72
Resistance Level $14.92 $57.15
Average True Range (ATR) 0.39 2.91
MACD -0.03 -0.92
Stochastic Oscillator 97.29 33.89

Price Performance

Historical Comparison
PK
GPCR

About PK Park Hotels & Resorts Inc.

Park Hotels & Resorts owns upper-upscale and luxury hotels, with 21,042 rooms across 33 hotels in the United States. Park also has interests through joint ventures in another 1,712 rooms in two US hotels. Park was spun out of Hilton Worldwide Holdings at the start of 2017, so most of its hotels are still under the Hilton brand. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.

About GPCR Structure Therapeutics Inc.

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

Share on Social Networks: